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INTRODUCTION
The most important danger to the uterine cervix is cancer.
Carcinoma of the cervix is second in frequency only to breast
cancer among the neoplasms causing CaJlcer deaths in females in
the United States& (29)
Considerable progress has been made in ttnderstanding the
spread of cancers of the uterine cervix since the Weithei.rn operation was devised and the first radiu.vn treatments given at the
begi~~ing

of the century.

The relationship of the zones of

effectiveness of internal radiu'U therapy and external ra.diation
to the routes of spread of carcinomas of the cervix is well
kncnm. (10)

These main routes of cancer spread are along the vaginal
mucosa, into the myometriu'U of the lower uterine segment, and
from there tQ the fundus&
lymph~tics

Then it spreads into the network of

of the paracervical areas and on to the parametria

and the pelvic wall lymphatics.
Cervical cancer may assume varied forms in its spread,
and the complications which may result from this requires an
adaptation of therapy to meet conditions, once treatment is
begun. (11)
The purpose of this study on the use of radiation in the
treatment
of cervical cancer is to survey the results of medical
.,
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literature on this topic arid to show the results of radiation
treatment on cases of cervical cancer treated at the University
of Nebraska College of Medicine.

HISTORY
The principles of the treatment of

squa~ous

cell carcinoma

of the cervix with irradiation has changed little since 1922.
The use of radiant energy in the treatment of cancer of the cervix
followed only two years after Becquerel inadvertently produced
his self-inflicted atomic energy burn by carr,ying a tube of radium
in his vest pocket.

Cancer of the cervix was the first of the

internal cancers to be successfully treated by radium, probably
due to its favorable anatomic pOSition centered within the pelvis.
As

tL~e

passed an American physician, Margaret Cleaves,

treated a patient with cancer of the cervix using radium, in 1903.
La.~er ~

1907, Dominici (Laboratoire Biologigue liu Radium) in

Paris announced his principles of filtered

radiation~

Radium

therapy then was developed principally in Stockholm and PariS.
By 1922 radiation therapy was a practical and useful agent in

cancer therapy, follOwing the introduction of external X-Ray as
a supplement to radium, in 1918.

B.Y 1929 the Radiumhemmet in Stockholm had adopted,the combined therap,r in the management of most cervical cancer.

But in

Germany during and following World War I, the Germans were unable
to acquire radium for medical use and thus their efforts turned
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toward roehtgen radiation.

Seitz and Wintz, using improved

apparatus of greater voltage and employing filtration in their
studies of irradiation of the pelvis by crossfiring through
multiple portals, published (1920) an early account encouraging
results in tne treatment of advanced cervical cancer.
In the 1930 l s the 400 KV, 500 KV and 800 KV units beca."Ile
available.

Higher doses were hence given to the pelvic walls.

By USing these doses and more efficient techniques, survival
rates were further improved.

Since World War II two new roentgen

ray generators, cobalt 60 units and 15 to 25 MEV betatrons, have
been used extensively in the management of cancers of the uterine
cervix. (10)

BACKGROUND INFORMATION
The ultimate aim of radiotherapy of cancer of the cervix is
to eradicate the primary disease and its extension into the surrounding tissues.

At the same time any injurious effects on the

viability and function of the other pelvic structures must be
minimized.
The effects of radiation are multiple..

One of these is the

cellular changes occurring, as first seen in the dividing nucleus.
The nucleus aSSUJl1es abnormal forms and there is an arrest of
division of the nucleus.

An indirect effect of radiation on the

tumor is due to the response of the stroma and blood vessels. (11)
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Anemic patients and patients with local and systemic infections do not tolerate irradiation as well as do normal individuals.
Thus the tumor response in these persons is not as satisfactory. (33)
The patient receiving radiotherapy should be on a high
protein, high calorie diet, increasing radiation tolerance.
STAGES AND SUBSTAGES
Cervical carcinoma is di videa and subdi videa. wi thin four
stages.

Stage I represents local disease confined to the cervix.

Stage II cases are subdivided into Stage II-A and II-B in order
to determine which cases are suitable for primary intracavitary
radi~~

therapy.

In Stage II-A the disease is limited to the

upper two thirds of the vagina and there may be minimal involvement of the parametria.

In Stage II-B there is involvement of

the lateral parametria and cancer extension almost to the pelvic
wall, but there is still tumor free space between the tumor and
the pelvic wall.
A

SUTVe.r

of the literature (7) shows that the incidence of

involvement of the pelvic wall lymph nodes is less than
in Stage I and Stage

II~A,

around

40

to

50

25

per cent

per cent in Stage II-B,

and above 60 per cent in Stage III cases.
The emphasiS should be on the local disease which can be
encompassed within the intracavitary radium therapy zone of
adequate dosage in Stage I and Stage II-A.

From Stage II-B

on the disease is beyond the reach of intracavitary radium therapy. (11)
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Stage III cases are also subdivided.

Stage III-A represents

a condition where only one pelvic wall is involved and Stage III-B
includes those cases with both pelvic walls, or one pelvic wall
and the la-wer one third of the vagina, involved.
cases have frozen or near-frozen pelves.

These Stage III.B

Their prognosis is

significantly worse than those patients of Stage III-A.
The Stage IV cases are subdivided into those in which the
disea.se is limited to the pelvis, and those in which there is
distant metastases.

Radical radiation thertp y is still indicate«

in Stage IV cases without distant metastases.
The following tables were compiled to show the treatment
policies in two different conditions.

Table I shows policies

for carcinoma of the uterine cervix used in one institution;
Table II

su~arizes

treatment policies for Primary Carcinoma of

the Cervical Stump.
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TABLE I
Policy of Treatment in Carcinomas of the Uterine Cervix
Stage
I

Treatment
13,000-12,000 mgh in 2-4 insertions
in 2-4 weeks, and
3,000-4,000 rads to parametria
and pelvic walls '**

Except.ions
lesion is large, 2,0004,000 rads are given first
to the whole pelvis in order
to secure optimal geometric
.conditions for intracavitary
radium therapy.
If

II-A

Same as Stage I

Same as Stage I

n-B

4,000 rads to the whole pelvis in
4 weeks with telecobalt followed
by 4,500-6,555 mgh in 2 insertions
il1 '2 iNeeks.

For some selected cases
of particularly infiltrative stony hard squamous
cell carcinomas in Stage
II-A, less whole-pelvis
radiation may be given
in order to give more
local radium therapy.
A hysterectomy is performed in the large endocervical squamous cell carcinoma
if regression is slow.

5,000 rads to the whole pelvis in
6 weeks with the telecobalt followed by 4,000-6500 mgh in one
insertion.

Same as Stage II-B

III-B

6,000 rads to the whole pelvis in
7 weeks with telecobalt occasionally with additional 2,000-3,000
mgh of radiulllo

IV

Palliative.

Same as Stage III-B when
no distant metastases.

cases of associated pregnancy, or up to 1 year postpartum,
4,000 rads are given to the whole pelvis because of increased
probability of metastatic disease in the pelvic wall lymph nodes.

i~In
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TABLE II

Policy of Treatment of Primary Cancer of the Cervical Stump
Stage

Treatment

I.

1.
2.

72 hour radium applications
3500 r trans vag. X-Ray (140 KV Al H'lL)
or if canal not located. Needle implant
6000 r.

II early

1.
2.

2000
4800
3500
2000

3.
4.
II advanced
III

r to entire pelvis in two weeks (10 RX)
hr. radium application
r trans vag. (140 KV 3mm Al HVL)
r to parametrium

1.
2.

2000 r to entire pelvis in two weeks
48 hour radium application **
3. 2000 r to entire pelvis in two weeks
4. 48 hour radium application
~~y substitute 400 r T.V. for the two radium
applications: 140 KV 3mm Al HVL

hooo -

6000 r Entire pelvis (lateral ports
in part)

IV

There have been many different techniques and applicators
developed for intracavitar,r radium, but the technique and appli,cator per se are far less important than adherence to principles
which have demonstrated their

mel~t

by favorable results over the

years. (32)
The dose to the parametria and pelvic wall depends upon the
total milligram hours, the location of radium within the pelviS,
and the respective loading of the tandem and colpostats.

The

main contributor to the pelvic wall lymph nodes from the intracavitary radium system is the uterine radium because of the
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central location.

The contribution of the vaginal radiation

depends upon the location of the radium.

This varies with age,

size of tumor, and distortion ca.used by disease.

'Vlith high

location within the pelvis the contribution to the obturator lymph
nodes is approximately 1,000 r for each

4,400

mgh.

The contribu-

tion to the hypogastric and external iliac lymph nodes is approximately half of that delivered to the obturator lymph nodes. (11)
Doses to Point A and B are calculated for the patients fram
tables.

Point A refers to a point 2 cm lateral to the cervical

canal and 2 cm from the mucosa of the lateral fornex and corresponds to the paracervical tissue.

Point B corresponds to the

pelvic wall and the obturator lymph nodes.
level as Point A and

5

It is on the same

cm lateral to the uterine canal.

The

limiting tolerance is measured at Point A with the intention of
delivering the maximum possible dose to Point B.

External radi-

ation is calculated for the mid-pelvic tumor dose.
CANCEROCIDAL A.'ifD TOLERANCE DOSES

The ability to cure a cancer effectively by radiation without
the destruction of the patient or her tissues is entirely dependent upon the ability to deliver to the cancerous area a sufficient dose of irradiation which kills the cancer and yet spares
the normal tissue in the tumor area.

So many variables modify

the response in anyone situation that a wide biological range is
used in expressing this cancerocidal dose.
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Also the time over

which the dose is given is important because of dose of 5000 r
in 24 hours would cause tissue necrosis, but when given over a
much longer period of 20 days, it would probably cause cancer
regression without severe reactions.

Another variable other than

the time dose relationship is the sensitivity of the tumor to
radiation.

..

In the absence of obvious overt infection, the dose of choice
is 8000 r delivered to Point A over a period of five weeks. (33,35)
It is generally conceded that full irradiation by intracavitary
sources to the entire pelvis is not practical because of the limitations dictated by the tolerances of the central structures.

Thus

to obtain cancerocidal dosages to the lateral pelvis, supplemented
therapy to the lateral areas is necessar,y.
Iso curves are used in determining the dose rate being delivered to specific points.

However, problems may occur due to

anatomical deviations such as:

the displacement farther or

closer to the sources, of the bladder and rectum; or the unusual
position or malposition of the applicator due to the tumor.
The use of immediate localizaing fiL'1ls in the operating room
serves as a good precaution.
Thus an important contribution to the radio

th~rapy

is the

introduction of direct measuring devices for monitoring the dose
rate being delivered to specific points.

The scintillation probe

counter is an excellent practical tool for this purpose. (33)
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The limiting

~actors

of external radiation are the skin

tolerance, minimized with rotational or multiple skin ports;
and the rectum.

The orthovoltage X-Ray machine, cobalt te1ether-

apy unit, Van de Graaff unit and the betatron, are available at
the present time for supplemental radiotherapy.
The cobalt teletherapy unit is used for most supplemental
~herapy in this hospital at the Uni versi ty of Nebraska.

The

dosages reaching the midparametria1 areas are increased without
increasing the sldn dosage itdt.h the cobalt unit, as compared
with dosages of the orthovo1tage X-Ray machine.

COMPLICATIONS OF

RADIOT~~PY

All radiation lihich is delivered to the pelvis for the treatment of cervical cancer causes residual damage to some degree to
all pelvic organs and structures.

The extent of the damage varies

from an insufficient allount to cause clinical symptoms, to an
amount suffioient to cause permanent loss of functions.
The small intestine is extremely sensitive to radiation and
accounts for the major incidence of radiation sickness; however,
the etiology of this illness cannot be accounted for entirely by
this intestinal radiation.

The skin, small intestines, large

intestine, bladder, ureters, uterus, vagina, bone and ovaries may
be involved and may lead to complications.
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Generally the radiation injuries heal spontaneously if
given enough time.

Biopsies of pathologic areas subsequent to

therapy should be delayed because radiated tissue is incapable
of withstanding and combating infection.

SUPER LETHA.LITY AND RADIO-RESISTANCE
Super lethality is used to describe the condition in which
the cancer lesion worsened after large doses of radiotherapy.
The decrease in favorable results in Stage I lesions with an increase in gamma radiation is explained by the fact that the major
portion of the cancer lies within the limits of safe tolerance
of therapeutic radiation dosage; and when additional radiation
is given, complications secondary to excessive radiation arise
and survival does not increase as might have been

expec~ed.

With later stages the major portion of tqe cancer is located
in an area receiving less than a cancerocidal dose and an increase
in dose will significantly increase the survival and will overshadow the secondary complications resulting from the radiation
exceeding the safe-tolerance level.
Re,dio-resistance in reference to cervical C8.,:ncer is really
the relative resistance or insensitivity of tissue to the effects
of radiation.

Any tissue, normal or malignant, can be destroyed

by radiation if the exposure is long enough.

Thus the cancer is

radio-resistant if it does not respond to the amount of radiation
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that is safe to apply.
"In our review of the cases it

found that

101a5

th~

maj ority

of failures of radiation as defined by local cervical persistance
of cancer were due to errors in application rather than due to
radioresistance." (32)
There have been many attempts to try to predict radioresistance prior to therapy.

These include grading the cells, histo-

logic changes with small amounts of radiation, RNA/DNA
tissue cultures, and cytological techniques.

ratio

Attempts to cOf'l.firm

these tests have not been uniform.
RESULTS OF IRRADIATION TREA~"T
AT THE UNIVERSITY OF NEBRASKA SINCE 1258
During the period fran January 1, 1958, to October.. , 1963,

99 patients with squamous cell carcinoma of the cervix were reviewed.

The ages, stages, type of treatment, and parity are

important considerations.

Table III which shows the distribu-

tion of ages of the University of Nebraska patients, follows:

TABLE III
Distribution by Age

20-29 30-39 40-49 50-59 60-69 70-79 80 and over
Stage
Stage
Stage
Stage
Stage
Total

11

0

I
II
III
IV

2

15
10

4
I

13

29

8

4
3
2

c
4
3
1

4
2

3
1

21

11

13

,.,;

2

3
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3
1
~

2

.;

1

9

3

Of this group one Stage 0 was treated with radiotherapy because
she was a poor surgical risk.

The remainder in this Stage were

treated surgically.
Summary of
In Stage I,

25

Sta~e

I

patients were studied.

The types of treat-

ment and survival rates are summarized below:
TABLE IV

Correlation of Treatment 'and Survival Rates in Stage I
Procedure

No.. of Patients

tper cent of 2 yr.
Alive,
survivals
Cancer Free
After 2 Year~
100
10

10

Wertheim
Hysterectomy
Only

TAIl Only
Vaginal
Hysterectomy

2

100
100

1

2*
1

3

1

33.3

9

8

88.9

Onlv

Radiation
and
SurgerY.
Radiation
Only

88 (average}
Totals
22
25
..'f()ne p atient has recorded recurrence after 25 months.
The average dose of radiation in roentgens delivered to
Point A in the 8 patients still living was 7,887 r.
ranged from

4,470

r to 10,900 r.

The dosage

Four patients died following

therapy; the average dose to Point A in this group was
However, 2 patients received 11,734 and 9,376 r.
receiving the

~734

6,575 r.

The patient

r had received radiation to the abdomen
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for another condition.

She also had had a TAR performed.

Due

to this prior radiotherapy, she perhaps was not as sensitive to
the radiation; for the dose she received is considered quite
adequate.

The patient receiving the 9,376 r dose also had an

anterior exenteration performed five months following the radiation therapy.
Two patients received doses too low to be cancerocidal.
However, one of these patients received 2,579 r to Point A.
w~en

she died with a coronary 27 months later, no sign of disease

was found.

The other patient had a BUN of

40 and an anemia.

The dose of 2,614 r to Point A seems very low and ineffective
as treatment.
In this Stage the complications-incidence was

33 1/3%. The

complications of the radiation therapy were cystitis in one patient, bowel obstruction in one patient, and proctitis in two
patients.

The therapy on the patient with the bowel obstruction

was stopped, but in the other patients, therapy was continued.
A comparison of the complications of radiation therapy and
the complications of surgery s·hows that there is a higher incidence
with radiation.

However, it must be kept in mind that surgery

patients were carefully screened and had no noticeable cancer
symptoms.

They were patients on whom the Papanicolaou smears were

done routinely and revealed abnormal smears with symptoms.
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The radiation-treated patients, on the other hand, either
came in with the complaint of vaginal bleeding, indicating later
Stage I carcinoma, or they were poor surgical risks.

It is true

that the survival of the surgery patients was higher, but it must
be noted that these patients were younger and in earlier Stage I
conditions as compared to the radiation-treated patients.

None

of the pathological reports on these surgery patients whowed
evidence of cancer spread to the nodes, thus indicating they
were a more favorable group for survival.
TABLE V

Radiation Data for Stage I
Stage I ••• living
Case II

Age

1

62

2

Total
Date
Treated m17. hr.

pt. A

r

Rectum
r

Remarks
Very obese; radium
only, cystitis
Obese
Proctitis
Bowel Obst.

10/61

5574

5768

4172

8
10

45
39
68
52
39

1/61
3/61
6/60
8/61
5/61

6600
6989
4658
4100
2190

10900
10564
4470
8495
8016

6216
6100
4385
6051
7050

11

30

2/61

6430

6191

3279

12

56

6/59

6083

8693

1488

- ..... -- -

7104

7887

5630

--

4

5

Averages
Stage I . ••• died

3

bb

510b

1540

2579

6

42

10/60

7035

11734

7

37

10/58

7916

9376

77

6/rJ9

2614
4776

2614
6575

9

Averages
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TAR and BSO prior
to radiotherapy
Wertheim - 6 wks.
after radium

!-1oilths
Alive Remarks
Died of coronary
27
No signoof disease
Hysterectomy, 147.
7896 26
TAR f'Tior Bad
to Aba.omen for
Another condition
Ant. Exenteration
7465 11
51. Proctitis
2
Anem •• BUN 40

--

7680

Summary of Stage I I
A total of 17 patients were seen with Stage II disease.
One patient refused therapy and was lost to followup in 1961.
The dose of radiation is tabulated in Table VI.
of 16 patients were treated with radiation.

Thus, a total

Nine (9) patients

are living, 7 of whom were treated more than two years ago.

One

patient was treated less than 6 months ago and the other patient
had a radical hysterectomy ohe year after radiation (dose to
Point A was 7,000 r).

The nodes were reported as negative

(no evidence of carcinoma.)

The last time this patient was seen,

metastatic lesion to the spine was found and this was treated
with radiation therapy.
The average dose to the patients still living was 8,932 r
to Point A.The average dose to Point A for patients who died
was 7,161 r, or a dose, which, in most instances, is less than
cancerocidal.

One of the deaths of these patients was follow-

ing anterior exenteration.
sidual carcinoma.

Another died with a eVA but had re-

One of these patients had received 9,900,r to

Point A but had a pelvic abscess.

With this infection the radia-

tion was probably not as effective.

Another patient developed a

perforated uterus following radiation and died with peritonitis,
secondary to this complication.
this group is 5:3%.

The 2 year survival rate for

This is considerably lower than survival

statistics from I,Yayo Clinic. (8)

Their rate for five years

was 72.8%.
-16-

TABLE VI
Radiation Data for Stage II
Stage II ••• living
Case Age Date
Total
110.
Treated :mJit. hr.
1
6(63
7746
12/59 10416
3

~~

r
9800
10470

Rectum
r
2350
10149

Pt. A

5
7

39
47

3 /60
9/61

7707
5760

10460
9077

6650
6260

10
11

48
51

5/60
2/62

7614
7078

8214
7081

7320
3542

12
13
14

51
42
64

5/59
2/61
1/61

3634
7471
6984

5917
10814
8560

7210
7874
7504

Averages - - -

7157

8932

6540

Stage II ••• died
2
5/60
35

5639

6173

6962

Months
Alive

Single Pul. Met.
treated with irrad.
nodes neg.;
exenteration
Anemia;
ESO 9/60;Bil.
uretero sigmoidostomy. Hydroureter
Mild proctitis
Rad. Hys. 1 year
after rad. Nodes
and uterus neg.
11/63 spine met.
Oolitis
Compression bladder
BUN 21.5

7

4

66

12/60

7734

9300

6780

7

6

88

7/59

6480

5384

6200

11

75
5158
90
2/58
9/60
32
58
6/58
Averages - - -

7300
3500
7564
5220
6234

6500
5570
9900
5300
7161

6180
5400
5800
5008
6050

35
17
10
22

8
9
15
17

Remarks

DieG! post.

Pelvic abscess
Oordotomy

Summary of Stage III

A total of 14 patients were seen with Stage III disease.
Only one patient is living following treatment, and she is free
of disease as of 3 years and 8 months post-treatment.
-17-

OPe

Exenteration
Died with OVA
Diabetes
Uterine perf.&
Peritonitis
BUN 23

The average

dose to Point A in this Stage III group of patients was 6563 r with
the range of 2944 r to 12,426 r.
is much higher in this group.

The incidence of complications

Complications included:

one intes-

tina1 obstruction, five ureteral obstruction, one proctitis, and
two patients with severe anemia.

One of these patients had a

draining fistula (complication from original surgical treatment
for carcinoma) two years prior to radiation.
TABLE VII
Radiation Data for Stage III
Stage III••• livin~
Gase Age Date
Total
No.
Treated MR. hr.
1 75
6266
4/60
Stage III ••• died
2
2/b1
47

7033

Rectum Months liemarks
Alive
r
r
7080 6062

pt. A

12426 12208

30

Partial bowel obst.
Hydronephritis
Anemia

4

72
51

5/58
9/58

----

4681

4290
4734

4110
6251

9
37

5
6

65
65

11/60
1/59

3059
6932

4464
6455

3820
7764

32
2

7

7?

12/58

4016

4367

3809

2

8
9

49
73

6/60
10/61

----

6940

9142
8600

6443
8600

40

10

73

3/60

5430

3675

3258

8

11

45

4/59

5355

9124

6512

11

12
13

67

56

2/60
5/60

1440
6322

2944
6463

2000
4198

3
12

14

58

8/59

6545

8633

7881

6

Averages- - 5250

6563

5912

3
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2

Parametritis;
Ureter obstruction
Obst. ureter
Diag. 2 yrs. prior;
Hys. 2 yrs. prior; Abscesf
Hydronephrosis
BUN 25-30
Met. to Skin
3000 r radiation prior
for draining fistula
Proctitis, anemia
Hematemisis,'dlverticulitis--stopped treat.
Uretero ohst. anemia
BUN 25
Refused further ext.
radiation; anemia
Bronchiogenic Ca

Summary of Stage rl
A total of five patients were seen with Stage IV disease.
Two patients were treated with radiation in this group.

One was

treated with an anterior exenteration yielding apparent success.
One patient refused therapy and the other patient died before therapy could be started.

The radiation therapy in these patients

was palliative because there was metastases in the lung in one
patient and the other patient had received prior ramation.

The

patient with lung metastases received a 7000 r mid-pelvic dose.
The survival rates for Stage III and IV are very poor and
0% for Stage IV radiation therapy; however, the number of patients
is too small to be Significant.

RESULTS OF DIAGNOSTIC STUDIES
Metastatic surveys were done on all Stage II and Stage IV
patients.

All Stage II cases were negative and four out of the

five Stage IV's were negative in the X-Ray studies done on this
group_

The intravenous pyelogram was the most consistent abnor-

mal finding with ather an obstructed ureter or a non-functioning
kidney on one side.

Seven IVP's were done on patients with Stage I

disease and three "I-rere abnormal.

According to one author, the

abnormal findings on pretreatment pyelograms diminish the chance
of the patient surviving .one year by

approxL~te1y

50%.

(31)

In this study conducted at the University of Nebraska, there
was a high number of patients in the 22-29 age group and two
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of these patients had invasive carcinoma.

One of these patients

with invasive carcinoma had been followed closely with Papanicolaou
sm.ears and after three dysplastic smears in a six month period,
a cone was 00 ne showing invasive squa..'1l0US cell carcinorna.

The

high number of patients in the lower age groups is probably due
to the type of patients seen..

Most of the patients were from. the

lower economic groups and many have been pregnant several times
in their teens.
Two year survivals "tiere calculated for the various stages.
S~~va1

ally.

statistics are reported as five year cures, tradition-

However, for evaluating results of treatment, data based

on survival without evidence of disease two years after treatment
for cancer of the cervix are also considered reliable. (33)
Eighty-five per cent of the patients with persistent cancer show
evidence of persistence within two years.
Between the second and fifth years subsequent to therapy,
only 10% of the patients treated for cervical cancer demonstrate
persistence of the cancer for the first time; and if the lL'1litations of the data are kept in mind, it is possible to evaluate
adequately the results of treatment at various periods.
It is of interest the percentages of blood types in this
study.

In this group of patients, 79 of the 99 had their blood

typed and
were

~.

46.7%

were

Q, 49.4%

Of note is the low

were!,

n~~ber

2.5%

of type
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were ~, and 1.3%

~,

but because the

study is small, this may be of little significance.
A study was done by Garriga (14) on the relations of blood
group to radiation response.

Groups! and

similar manner and when compared to group
signific~~tly

~

2,

responded in a very
the latter had, a

better response to radiation therapy.
CONCLUSIONS

1.

The primary treatment for invasive cervical carcinoma at
the University of Nebraska Hospital has been intracavitary
radium supplemented with external radiation.
would be a few highly favorable Stage

lIS

The exception

and especially those
n~

in the younger age groups where castration is
2.

desirable.

SurgerJ is apparently more effective in Stage I, but the patients were favorably selected whereas the patients with
radiotherapy were not selected and had later Stage I disease.

3. Salvage rates are low in the Stage II, III, and IV groups
and also in the: patients in wh6mthe initial treatment
was inadequate.

4.

Many failures of radiation are due to errors in application
rather than due to radioresistance.

5.. The status' of the urinary tract markedly i.."lfluences the survival rates ..

6. Earlier diagnosis through public education and more routine
pelvic examinations combined with Papanicolaou smears at
regular intervals promise the most
thus benefiting the patient

)n. th

-21-

L~ediate

early diagnosis,

this disease.

7. Carcinoma of the cervix is a curable disease

when

detected

in its earliest stages.
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